secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-06-22T20:05:37+00:00
Accession:  0001193125-26-277513
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Director Michelle Doig resigns; shareholders elect two Class I directors at annual meeting
--------------------------------------------------------------------------------

- Michelle Doig resigned as Class I director upon completion of her term on June 16, 2026; resignation not due to any disagreement.
- Shareholders elected Peter Lebowitz (31,822,504 votes for) and Frank McCormick (25,654,119 votes for) as Class I directors.
- Ratification of Deloitte & Touche LLP as independent auditor for FY 2026 approved with 34,535,875 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/0001193125-26-277513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/d137002d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-277513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer